🔴 Abcellera Biologics is trading 7% down today after $200 million offering raises dilution concerns

Abcellera Biologics is trading 7% down at $10.53 as investors continue reacting to its $200 million public offering and dilution concerns.

• The offering was priced at $9.75 per share, involving 17.4 million common shares plus pre-funded warrants, and supports pipeline development.
• The Nasdaq Composite is down 0.55%, but the company-specific financing appears to be the primary catalyst.
• Shares fell from $12.01 on August 19, 2026, to $11.32 on August 21, 2026, after an earlier clinical-trial-driven rally.